Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Based on Hospital...

    Based on Hospital data, NPPA fixed price of Calcium Carbonate tab, 4 other formulations

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2020-03-10T10:30:42+05:30  |  Updated On 10 March 2020 10:31 AM IST
    Based on Hospital data, NPPA fixed price of Calcium Carbonate tab, 4 other formulations

    New Delhi: Based on Institutional Data received from Hospitals, the National Pharmaceutical Pricing Authority (NPPA) has fixed Ceiling Price of Calcium Carbonate 500mg Tablets under para 19 of DPCO, 2013 along with 4 other formulations.

    Besides fixing the price, NPPA in its recent most meeting further ordered that action may be taken against Max hospital, Gurugram for sale of Calcium Carbonate 500 mg tablet for violations of the provisions of DPCO 2013.

    The Authority in its meeting noted that to fix the ceiling price of the scheduled formulations based on the communication of Department of Pharmaceuticals (DOP) dated 05.02.2019, in cases where no market data is available, NPPA had taken extra efforts to collect the institutional data. Letters were issued to Director General Health Services (DGHS), Central drug procurement agencies; state drug procurement agencies, state drug controller (SDC), Central/State Government Hospitals and private Hospitals, etc in order to obtain the data from the required Institutions.

    The services of Standing National Committee on Medicines (SNCM) were also obtained in collecting the requisite data. Despite such elaborate efforts, data could not be collected in respect of some of the scheduled formulations as stipulated. However, NPPA had, on own initiative, put the data in public domain to invite concerns, if any.

    The Authority further noted the representations received from representation from Confederation of Indian Industry (CII), New Delhi and Indian Pharmaceutical Alliance (IPA), Mumbai for providing 24% margin on the draft calculation uploaded in NPPA's website based on its earlier decision in the meeting dated 20.01.2020. In this connection, the Authority took cognizance of the fact that NPPA had earlier fixed the ceiling price of certain scheduled formulations based on institutional data by giving nil margin for which representations were received from the state agencies of Karnataka, West Bengal, Rajasthan, Assam and Bihar. The agencies stated that they were not able to procure citing the inability to supply within the ceiling price notified by NPPA. The Hon'ble High Court of Madhya Pradesh had also passed an order in this regard. Accordingly, the Authority agreed to allow 24% margin on average procurement price at an institutional level.

    The Authority deliberated upon the matter at length and opined that delay in giving the ceiling price of these scheduled formulations would delay the benefit of ceiling price being passed on to the consumers.
    Accordingly, the Authority approved the ceiling price of 5 scheduled formulations based on the institutional data available in public interest as detailed below
    Formulation Approved Ceiling Price (ex GST)
    1. Calcium Carbonate 500mg Tablet-Rs. 1.69 per Tablet
    2. Ferrous Salt 100mg + Folic Acid 500mcg tablet-Rs. 0.23 per Tablet
    3. All-trans Retinoic Acid 10mg capsule-Rs. 80.05 per capsule
    4. Daunorubicin 5mg/ml injection (20mg pack)-Rs. 237.98 per pack
    5. Ethyl Alcohol (Denatured) 70% solution-Rs. 0.41 per ml

    The Authority further directed that action may be taken against Max hospital, Gurugram for sale of Calcium Carbonate 500 mg tablet for violations of the provisions of DPCO 2013.

    nppacalcium-carbonate-tabprice-fixationdepartment-of-pharmaceuticalsnational-pharmaceutical-pricing-authority

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok